A Phase II Study for Metabolic in Vivo Response Monitoring With Sequential 18fdg-Pet-Ct During Treatment With the EGFR-monoclonal-antibody Cetuximab in Metastatic Colorectal Cancer: The Heidelberg REMOTUX Trial
BMC Cancer - United Kingdom
doi 10.1186/1471-2407-12-108
Full Text
Open PDFAbstract
Available in full text
Date
March 22, 2012
Authors
Publisher
Springer Science and Business Media LLC